ZAI Lab

downturn economy markets bank negative fall down

Amgen-Zai stomach cancer asset loses OS benefit in final analysis

The final analysis in a phase 3 study of Amgen's Zai Labs-partnered bemarituzumab showed that the drug's benefits had lessened from the interim analysis.

Zoey Becker Sep 3, 2025 4:33pm

Close up shot of the target from a dart game

Amgen, Zai say stomach cancer candidate hits phase 3 mark

Jun 30, 2025 10:36am

Seagen finally finds new CEO—Chutes & Ladders

Nov 11, 2022 9:30am

Zai Lab to shop around CD47 after deprioritizing internal work

Aug 10, 2022 10:40am

Alchemab CEO resigns citing 'personal reasons'—Chutes & Ladders

May 27, 2022 9:30am

Camp4 taps former Translate CMO for same role—Chutes & Ladders

Mar 18, 2022 9:30am